Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

BACKGROUND: Ribociclib (RIBO) and palbociclib (PALBO), combined with letrozole (LET), have been evaluated as treatments for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in separate Phase III randomized controlled trials (RCTs), but not head-to-h...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Manag Res
Autors principals: Tremblay, Gabriel, Chandiwana, David, Dolph, Mike, Hearnden, Jaclyn, Forsythe, Anna, Monaco, Mauricio
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5968783/
https://ncbi.nlm.nih.gov/pubmed/29861642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S163478
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars